371 related articles for article (PubMed ID: 28081304)
1. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study.
Watanabe T; Kuranami M; Inoue K; Masuda N; Aogi K; Ohno S; Iwata H; Mukai H; Uemura Y; Ohashi Y
Cancer; 2017 Mar; 123(5):759-768. PubMed ID: 28081304
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of Paclitaxel in node-positive breast cancer.
Roy C; Choudhury KB; Pal M; Saha A; Bag S; Banerjee C
Indian J Cancer; 2012; 49(3):266-71. PubMed ID: 23238142
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.
Mackey JR; Martin M; Pienkowski T; Rolski J; Guastalla JP; Sami A; Glaspy J; Juhos E; Wardley A; Fornander T; Hainsworth J; Coleman R; Modiano MR; Vinholes J; Pinter T; Rodríguez-Lescure A; Colwell B; Whitlock P; Provencher L; Laing K; Walde D; Price C; Hugh JC; Childs BH; Bassi K; Lindsay MA; Wilson V; Rupin M; Houé V; Vogel C;
Lancet Oncol; 2013 Jan; 14(1):72-80. PubMed ID: 23246022
[TBL] [Abstract][Full Text] [Related]
4. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
[TBL] [Abstract][Full Text] [Related]
5. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197.
Goldstein LJ; O'Neill A; Sparano JA; Perez EA; Shulman LN; Martino S; Davidson NE
J Clin Oncol; 2008 Sep; 26(25):4092-9. PubMed ID: 18678836
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
[TBL] [Abstract][Full Text] [Related]
7. Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.
Swain SM; Tang G; Geyer CE; Rastogi P; Atkins JN; Donnellan PP; Fehrenbacher L; Azar CA; Robidoux A; Polikoff JA; Brufsky AM; Biggs DD; Levine EA; Zapas JL; Provencher L; Northfelt DW; Paik S; Costantino JP; Mamounas EP; Wolmark N
J Clin Oncol; 2013 Sep; 31(26):3197-204. PubMed ID: 23940225
[TBL] [Abstract][Full Text] [Related]
8. A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study.
Vici P; Brandi M; Giotta F; Foggi P; Schittulli F; Di Lauro L; Gebbia N; Massidda B; Filippelli G; Giannarelli D; Di Benedetto A; Mottolese M; Colucci G; Lopez M
Ann Oncol; 2012 May; 23(5):1121-1129. PubMed ID: 21965475
[TBL] [Abstract][Full Text] [Related]
9. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.
Martín M; Ruiz A; Ruiz Borrego M; Barnadas A; González S; Calvo L; Margelí Vila M; Antón A; Rodríguez-Lescure A; Seguí-Palmer MA; Muñoz-Mateu M; Dorca Ribugent J; López-Vega JM; Jara C; Espinosa E; Mendiola Fernández C; Andrés R; Ribelles N; Plazaola A; Sánchez-Rovira P; Salvador Bofill J; Crespo C; Carabantes FJ; Servitja S; Chacón JI; Rodríguez CA; Hernando B; Álvarez I; Carrasco E; Lluch A
J Clin Oncol; 2013 Jul; 31(20):2593-9. PubMed ID: 23733779
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of anemia, neutropenia and skin toxicities in standard or dose-dense doxorubicin/cyclophosphamide (AC)-paclitaxel or docetaxel adjuvant chemotherapy in breast cancer.
Schwartz J; Domchek SM; Hwang WT; Fox K
Ann Oncol; 2005 Feb; 16(2):247-52. PubMed ID: 15668278
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer.
Puhalla S; Mrozek E; Young D; Ottman S; McVey A; Kendra K; Merriman NJ; Knapp M; Patel T; Thompson ME; Maher JF; Moore TD; Shapiro CL
J Clin Oncol; 2008 Apr; 26(10):1691-7. PubMed ID: 18316792
[TBL] [Abstract][Full Text] [Related]
12. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.
Jones SE; Savin MA; Holmes FA; O'Shaughnessy JA; Blum JL; Vukelja S; McIntyre KJ; Pippen JE; Bordelon JH; Kirby R; Sandbach J; Hyman WJ; Khandelwal P; Negron AG; Richards DA; Anthony SP; Mennel RG; Boehm KA; Meyer WG; Asmar L
J Clin Oncol; 2006 Dec; 24(34):5381-7. PubMed ID: 17135639
[TBL] [Abstract][Full Text] [Related]
13. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.
Eiermann W; Pienkowski T; Crown J; Sadeghi S; Martin M; Chan A; Saleh M; Sehdev S; Provencher L; Semiglazov V; Press M; Sauter G; Lindsay MA; Riva A; Buyse M; Drevot P; Taupin H; Mackey JR
J Clin Oncol; 2011 Oct; 29(29):3877-84. PubMed ID: 21911726
[TBL] [Abstract][Full Text] [Related]
14. Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial.
Shimozuma K; Ohashi Y; Takeuchi A; Aranishi T; Morita S; Kuroi K; Ohsumi S; Makino H; Katsumata N; Kuranami M; Suemasu K; Watanabe T; Hausheer FH
Support Care Cancer; 2012 Dec; 20(12):3355-64. PubMed ID: 22584733
[TBL] [Abstract][Full Text] [Related]
15. Comparison of EQ-5D scores among anthracycline-containing regimens followed by taxane and taxane-only regimens for node-positive breast cancer patients after surgery: the N-SAS BC 02 trial.
Shiroiwa T; Fukuda T; Shimozuma K; Kuranami M; Suemasu K; Ohashi Y; Watanabe T
Value Health; 2011; 14(5):746-51. PubMed ID: 21839414
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study.
Au HJ; Eiermann W; Robert NJ; Pienkowski T; Crown J; Martin M; Pawlicki M; Chan A; Mackey J; Glaspy J; Pintér T; Liu MC; Fornander T; Sehdev S; Ferrero JM; Bée V; Santana MJ; Miller DP; Lalla D; Slamon DJ;
Oncologist; 2013; 18(7):812-8. PubMed ID: 23814044
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.
Mamounas EP; Bryant J; Lembersky B; Fehrenbacher L; Sedlacek SM; Fisher B; Wickerham DL; Yothers G; Soran A; Wolmark N
J Clin Oncol; 2005 Jun; 23(16):3686-96. PubMed ID: 15897552
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer.
Schneeweiss A; Marmé F; Ruiz A; Manikhas AG; Bottini A; Wolf M; Sinn HP; Mansouri K; Kennedy L; Bauknecht T
Ann Oncol; 2011 Mar; 22(3):609-617. PubMed ID: 20732932
[TBL] [Abstract][Full Text] [Related]
19. Sequential adjuvant docetaxel and anthracycline chemotherapy for node positive breast cancers: a retrospective study.
Bulent Akinci M; Algin E; Inal A; Odabas H; Berk V; Coskun U; Uyeturk U; Isikdogan A; Aksoy S; Civelek B; Sevinc A; Buyukberber S
J BUON; 2013; 18(2):314-20. PubMed ID: 23818340
[TBL] [Abstract][Full Text] [Related]
20. A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer.
Perez EA; Geeraerts L; Suman VJ; Adjei AA; Baron AT; Hatfield AK; Maihle N; Michalak JC; Kuross SA; Kugler JW; Lafky JM; Ingle JN
Ann Oncol; 2002 Aug; 13(8):1225-35. PubMed ID: 12181246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
